5345 - Short-term Clinical Outcomes of Robotic-Assisted Total Mesorectal Excision in Rectal Cancer after concurrent chemoradiotherapy

Background

To evaluate the short-term oncological outcomes of robotic-assisted total mesorectal excision (TME) in patients with rectal cancer after neoadjuvant CCRT (concurrent chemoradiotherapy).

Methods

We enrolled 120 patients with stages I-IV rectal cancer who underwent robotic-assisted total mesorectal excision (TME) after neoadjuvant concurrent chemoradiotherapy at a single institution between July 2013 and November 2017.

Results

Of the 120 patients enrolled, all of them underwent preoperative concurrent chemoradiotherapy. Furthermore, among these 120 patients, 34 (28.3%) achieved a pathologic complete response and 19 people had local or distant recurrences. In a median follow up of 24 months, the 2-year disease-free survival(DFS) and overall survival(OS) were and 84% and 86%.

Conclusions

The results demonstrate that robotic-assisted TME for patients with rectal cancer after neoadjuvant CCRT (concurrent chemoradiotherapy) is effective and for patient with tumor invaded to bladder, prostate or uterus, neoadjuvant chemotherapy is a safe and effective way for organ-preserving instead of salvage surgery.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.